CMS Maintains Hardline Approach In New-Tech Add-On Payment Reviews
This article was originally published in The Gray Sheet
The Medicare agency raised significant questions about the qualifications for all five device applicants for FY 2017 new-technology add-on payments in its latest hospital inpatient proposed rule.
You may also be interested in...
The Medicare hospital inpatient final rule gives new technology add-on payments to just two devices, Ellipse Technologies's Magec spinal bracing and distraction system, and Gore's Excluder iliac branch endoprosthesis. Two other requests were turned down, and another device was not FDA-approved in time.
The positive hospital inpatient reimbursement decision for recently launched Medtronic and CR Bard peripheral artery devices follows prior positive policy rulings in the outpatient setting. Meanwhile, CMS rejected Boston Scientific's new-technology add-on application for the Watchman stroke device, but the agency did establish a pricier payment category for the new procedure.
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.